https://scholars.lib.ntu.edu.tw/handle/123456789/479659
標題: | Arguments in favour of remdesivir for treating SARS-CoV-2 infections | 作者: | Ko W.-C. Rolain J.-M. Lee N.-Y. Chen P.-L. Huang C.-T. PING-ING LEE PO-REN HSUEH |
公開日期: | 2020 | 起(迄)頁: | 105933 | 來源出版物: | International Journal of Antimicrobial Agents | URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/479659 | ISSN: | 0924-8579 | DOI: | 10.1016/j.ijantimicag.2020.105933 | SDG/關鍵字: | aciclovir; aristeromycin; favipiravir; galidesivir; penciclovir; remdesivir; ribavirin; RNA directed RNA polymerase; adenosine phosphate; alanine; antivirus agent; DNA directed RNA polymerase; remdesivir; amino acid substitution; antibiotic resistance; antiviral activity; clinical effectiveness; concentration response; coronavirus disease 2019; coronavirus disease 2019; Coronavirus infection; drug half life; drug tolerability; Ebola hemorrhagic fever; Editorial; human; nonhuman; priority journal; protein targeting; SARS-related coronavirus; Severe acute respiratory syndrome coronavirus 2; treatment outcome; treatment response; virus load; animal; Betacoronavirus; clinical trial (topic); Coronavirus infection; drug effect; enzymology; pandemic; virus pneumonia; Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; DNA-Directed RNA Polymerases; Humans; Pandemics; Pneumonia, Viral |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。